Abstract: A single injection that manages post-surgical pain for up to 72 hours without an opioid pump is not a convenience—it is a change in the economics and safety profile of surgery. The bupivacaine liposome injectable suspension is that product: a long-acting local anesthetic formulated with multivesicular liposomes that release bupivacaine gradually after infiltration or nerve block. The global bupivacaine liposome injectable suspension market is projected to grow from USD 538.75 million in 2023 to USD 907.30 million by 2030, at a CAGR of 8.60%. Pacira Pharmaceuticals’ EXPAREL remains the reference product, but the competitive landscape is shifting: Jiangsu Hengrui obtained the world’s first generic approval in China in 2022, and Hunan Kelun became the second approved Chinese product in August 2024. This analysis examines why liposomal bupivacaine is becoming a standard component of multimodal analgesia, and what hospital procurement teams and formulary committees must weigh before adopting a product whose value depends on surgical protocol integration, not just drug efficacy.

What Is Bupivacaine Liposome Injectable Suspension?
Bupivacaine Liposome Injectable Suspension is a long-acting local anesthetic used primarily for post-operative pain management. The active ingredient, bupivacaine, is formulated using liposomal technology to extend the drug’s release time. Through the controlled release of the liposomes, bupivacaine provides sustained analgesia for up to 72 hours, reducing the need for opioid medications and minimizing opioid-related side effects and dependence. The drug is used for pain management after various surgical procedures, including orthopedic and thoracic surgeries, and can significantly enhance the post-operative recovery process. It is often part of multimodal pain management strategies, offering ease of use without special equipment and improving patient compliance.

The distinction from standard bupivacaine is the pharmacokinetics. Standard bupivacaine provides analgesia for hours; the liposomal formulation extends that to days by encapsulating the drug in multivesicular liposomes that release it slowly. The clinical implication is not merely longer duration—it is the potential to reduce or eliminate opioid use during the critical early post-operative period, when patients are most vulnerable to respiratory depression and dependency.

Market Size and Competitive Landscape
According to QYResearch’s Global Bupivacaine Liposome Injectable Suspension Market Report 2024–2030, the global market is projected to grow from USD 538.75 million in 2023 to USD 907.30 million by 2030, at a CAGR of 8.60%. Key manufacturers include Pacira Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals.

The competitive structure is unusual: for most of the product’s commercial life, it was a single-source franchise. Pacira’s EXPAREL, approved by the FDA in 2011, was the only liposomal bupivacaine product in major markets. That exclusivity is now eroding. In 2022, Jiangsu Hengrui Pharmaceuticals obtained approval in China, becoming the world’s first generic version of the product. In China, besides Hengrui, Kelun Pharmaceutical and Zhejiang Sundoc Pharmaceutical have also entered this market. In October 2024, Kelun’s subsidiary, Hunan Kelun Pharmaceutical, received approval for its Bupivacaine Liposome Injectable Suspension, considered equivalent to passing consistency evaluation—making it the second approved product in China.

Pacira’s own commercial performance illustrates the product’s resilience and its challenges. EXPAREL net product sales were USD 575.1 million in 2025, a 5% increase over the USD 549.0 million reported in 2024 . The growth came despite the presence of a generic competitor in the U.S. market and ongoing patent litigation. In October 2025, Pacira received Paragraph IV certifications from two Chinese generic manufacturers—WhiteOak and Qilu—each seeking FDA authorization for a generic EXPAREL, and Pacira filed patent infringement suits in response . The message is clear: the product’s commercial value has attracted generic competition, and the legal battles will shape market share through the forecast period.

China: The Growth Frontier
With the accelerated aging of China’s population and a steadily increasing number of surgical patients, there is growing demand for long-term, sustained, and safe postoperative pain relief drugs. Bupivacaine Liposome Injectable Suspension has broad market prospects in China.

The Chinese competitive landscape is already crowded for a product that was a monopoly elsewhere. Hengrui’s approval in 2022 was followed by Kelun’s in 2024, and Zhejiang Sundoc is also present. The entry of multiple domestic manufacturers has a predictable effect: price competition. For hospital formulary committees, the availability of multiple approved products creates leverage—but it also creates a selection problem. A generic that is bioequivalent does not necessarily perform identically in every surgical protocol, and the clinical evidence base for each product may differ.

China’s regulatory pathway has also been supportive. Hengrui conducted a human bioequivalence study comparing its product to EXPAREL as the reference, with the trial completed and registered on the China Drug Trials platform . Kelun’s product was included in the 2024 National Reimbursement Drug List, a significant milestone for patient access and hospital adoption . For a hospital in China, the decision to use a liposomal bupivacaine product now involves not only clinical considerations but reimbursement status, manufacturer relationships, and the growing body of real-world evidence from Chinese surgical populations.

An Overlooked Observation: The Real Barrier Is Surgical Protocol Integration, Not Drug Price
Hospitals and formulary committees comparing bupivacaine liposome injectable suspension products often focus on acquisition cost per vial. This matters for budget management, but it misses the variable that determines whether the product delivers value: surgical protocol integration.

Liposomal bupivacaine is not a drop-in replacement for standard bupivacaine. Its efficacy depends on correct administration technique—infiltration into the surgical site before closure, or nerve block at the appropriate anatomical location. A surgeon who administers it incorrectly, or a hospital that lacks a standardized enhanced recovery after surgery (ERAS) protocol that incorporates the product, will not realize the opioid reduction that the clinical trials demonstrated. The drug’s value is realized only when it is embedded in a care pathway, not when it is stocked in the pharmacy.

This has a direct procurement implication. The question to ask is not “what is the price per vial” but “what is the institutional protocol for use, and what evidence supports the opioid reduction in our patient population?” A hospital that purchases the cheapest available product without a protocol to ensure proper administration is buying a drug, not a clinical outcome.

A second overlooked factor: the generic competition in China is not a simple price story. Hengrui and Kelun are both established pharmaceutical companies with hospital relationships and sales forces. Their entry into the market may expand total adoption rather than simply divide an existing pie—because they have the commercial infrastructure to educate surgeons and drive protocol change. The Chinese market may grow faster than the global average precisely because domestic competition is accelerating adoption, not just eroding price.

A third factor: the U.S. patent landscape creates uncertainty that procurement teams should monitor. Pacira’s patent litigation with WhiteOak and Qilu will determine whether additional generic versions enter the U.S. market and when . A hospital system planning a multi-year formulary contract should consider whether the product’s exclusivity position is stable, or whether a generic entry could change the pricing dynamic mid-contract.

Outlook
The bupivacaine liposome injectable suspension market will grow at a strong 8.60% CAGR, anchored by the global shift toward opioid-sparing analgesia and the expansion of surgical volume in aging populations. The competitive dynamic is shifting from Pacira’s single-source dominance to a multi-player landscape in China and a contested one in the U.S.

For hospital procurement teams and formulary committees, the evaluation criteria extend beyond price per vial. Institutional protocol readiness and surgeon training support, clinical evidence in the specific surgical specialties the hospital serves, reimbursement status (particularly in China), and the manufacturer’s supply reliability and patent position should carry weight comparable to headline pricing. The cheapest liposomal bupivacaine may prove the most expensive per patient outcome if it is administered without protocol support, used in procedures where its benefit is unproven, or sourced from a supplier whose exclusivity is about to expire.

The product is a vial of milky suspension. What it delivers is 72 hours of pain control—and, if integrated correctly, a surgery that requires fewer opioids and discharges patients sooner. The decision to specify the right one is not a pharmacy purchasing detail; it is a surgical care decision.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp